Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

11 Aug 2021 11:30

RNS Number : 3165I
Amryt Pharma PLC
11 August 2021
 

 

 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are at- tachedii:

 

Amryt Pharma PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

 

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

X

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

EdgePoint Investment Group Inc.

City and country of registered office (if applicable)

Toronto, Canada

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

06/08/2021

6. Date on which issuer notified (DD/MM/YYYY):

10/08/2021

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights at- tached to shares (to- tal of 8. A)

% of voting rights through financial in- struments

(total of 8.B 1 + 8.B 2)

 

Total of both in % (8.A + 8.B)

Total number of voting rights of is- suervii

Resulting situation on the date on which

threshold was crossed or reached

 

0%

 

3.71%

 

3.71%

 

307,118,662

Position of previous notification (if applicable)

 

0%

 

7.93%

 

7.93%

 

       

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

 

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

 

Type of financial in- strument

 

Expiration datex

 

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

 

% of voting rights

ADSs US03217L1061

N/A

N/A

11,389,820

3.71%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

11,389,820

3.71%

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration datex

Exercise/

Conversion Pe- riod xi

Physical or

cash settlementxii

Number of voting rights

 

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

          
 

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

X

 

 

Namexv

% of voting rights if it equals or is higher than the notifiable

threshold

% of voting rights through financial in- struments if it equals or is higher than the

notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

EdgePoint Investment Group Inc.

 

 

 

EdgePoint Wealth Manage- ment Inc.

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

 

11. Additional informationxvi

Full chain of controlled undertakings:

 

EdgePoint Investment Group Inc. EdgePoint Wealth Management Inc.

     

 

Place of completion

Toronto, Canada

Date of completion

10/08/2021

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBFLFFFVLLBBK
Date   Source Headline
24th Apr 20177:00 amRNSFirst Patient Enrolled
10th Apr 20175:21 pmRNSDirector/PDMR Shareholding
6th Apr 20174:13 pmRNSPosting of Annual Report 2016 and Notice of AGM
30th Mar 20177:00 amRNSFinal Results
28th Mar 20177:00 amRNSPhase 3 Clinical Trial for AP101 commenced
27th Mar 20177:00 amRNSSenior Management Appointment
8th Mar 20177:00 amRNSNotice of Results
6th Mar 20177:00 amRNSAP101 trial discussions completed with FDA & EMA
9th Feb 20177:00 amRNSDirectorate Change
7th Feb 20177:00 amRNSGrant of patent in Japan for AP101 (Episalvan)
6th Feb 20177:00 amRNSPre-clinical study results
5th Dec 20167:00 amRNSTransformational Licence Agreement
2nd Dec 20167:00 amRNSEUR20m Facility with European Investment Bank
7th Nov 20167:00 amRNSOrphan drug designation for Acromegaly Compound
19th Sep 20167:00 amRNSAppointment of Chief Medical Officer
13th Sep 20167:00 amRNSGrant of US patent for lead drug, Episalvan
13th Sep 20167:00 amRNSHalf-year Report
7th Jul 201612:54 pmRNSResult of AGM
27th Jun 20167:00 amRNSMarkus Ziener appointed as Non-Executive Director
9th Jun 20167:00 amRNSFinancial Results
2nd Jun 20164:34 pmRNSNotice of Results
21st Apr 20164:35 pmRNSHolding(s) in Company
19th Apr 20167:00 amRNSAdmission to trading on AIM and ESM
18th Apr 20162:30 pmRNSESM Schedule 1 Update
18th Apr 20162:30 pmRNSSchedule One update - Fastnet Equity plc
18th Apr 201612:41 pmRNSResult of General Meeting and Change of Name
31st Mar 20167:35 amRNSESM Schedule 1
31st Mar 20167:30 amRNSSchedule One - Fastnet Equity plc
31st Mar 20167:30 amRNSRestoration - Fastnet Equity plc
31st Mar 20167:00 amRNSProposed Acquisition of Amryt Pharmaceuticals
22nd Feb 20167:30 amRNSSuspension - Fastnet Equity plc
22nd Feb 20167:30 amRNSPotential Acquisition and Statement re Suspension
21st Dec 20157:01 amRNSAppointment of Non-executive Director
21st Dec 20157:00 amRNSInterim Results
18th Dec 20157:00 amRNSDemerger of Oil and Gas Assets
30th Sep 20153:12 pmRNSResult of Annual General Meeting
4th Sep 20157:00 amRNSFinal Results
28th Aug 20153:31 pmRNSResult of General Meeting
11th Aug 20153:35 pmRNSProposed adoption of Investing Policy/Notice of GM
3rd Jul 20153:22 pmRNSDirector/PDMR Shareholding
26th Jun 20152:45 pmRNSDirector/PDMR Shareholding
2nd Jun 20152:27 pmRNSHolding(s) in Company
1st Jun 20157:00 amRNSCorporate Update
26th Mar 20157:00 amRNSCeltic Sea Portfolio
27th Jan 201512:56 pmRNSDirectorate Change
9th Jan 201512:49 pmRNSHolding(s) in Company
2nd Jan 20157:00 amRNSExpiry of Tendrara Option Agreement
19th Dec 20147:00 amRNSInterim Results
10th Dec 20147:00 amRNSBoard changes & operational update
1st Dec 20143:00 pmRNSResponse to press speculation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.